
Susana T Valente

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6154291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
2	InÂVivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock―Strategy for HIV-1 Treatment. Cell Reports, 2017, 21, 600-611.	6.4	189
3	The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio, 2015, 6, e00465.	4.1	188
4	An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. Cell Host and Microbe, 2012, 12, 97-108.	11.0	159
5	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	30.7	146
6	Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2195-2208.	3.2	91
7	HIV-1 Capsid Inhibitors as Antiretroviral Agents. Current HIV Research, 2016, 14, 270-282.	0.5	67
8	Targeting HIV Transcription: The Quest for a Functional Cure. Current Topics in Microbiology and Immunology, 2015, 389, 121-145.	1.1	66
9	Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice. Current HIV Research, 2015, 13, 64-79.	0.5	59
10	Block-And-Lock: New Horizons for a Cure for HIV-1. Viruses, 2020, 12, 1443.	3.3	58
11	Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat. MBio, 2019, 10, .	4.1	56
12	Inhibition of HIV-1 Gene Expression by a Fragment of hnRNP U. Molecular Cell, 2006, 23, 597-605.	9.7	52
13	HIV-1 mRNA 3′ End Processing Is Distinctively Regulated by eIF3f, CDK11, and Splice Factor 9G8. Molecular Cell, 2009, 36, 279-289.	9.7	52
14	The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders. Frontiers in Microbiology, 2015, 6, 1164.	3.5	51
15	Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat. Epigenetics and Chromatin, 2019, 12, 23.	3.9	46
16	Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription. MBio, 2019, 10, .	4.1	38
17	Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription. Current Pharmaceutical Design, 2017, 23, 4079-4090.	1.9	38
18	Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology, 2012, 1, 668-697.	2.8	36

SUSANA T VALENTE

#	Article	IF	CITATIONS
19	Inhibition of HIV-1 replication by eIF3f. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4071-4078.	7.1	35
20	The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro–Cortistatin A. Journal of Infectious Diseases, 2021, 223, S46-S53.	4.0	27
21	β-cyclodextrin polymer/Soluplus® encapsulated Ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV. International Journal of Pharmaceutics, 2020, 589, 119863.	5.2	23
22	Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure. Viruses, 2020, 12, 529.	3.3	23
23	Cellâ€Permeable Peptides Containing Cycloalanine Residues. Angewandte Chemie - International Edition, 2016, 55, 12637-12642.	13.8	22
24	Didehydro-Cortistatin A: a new player in HIV-therapy?. Expert Review of Anti-Infective Therapy, 2016, 14, 145-148.	4.4	21
25	Identification of potent small molecule inhibitors of SARS-CoV-2 entry. SLAS Discovery, 2022, 27, 8-19.	2.7	20
26	The Tat inhibitor didehydroâ€cortistatin A suppresses SIV replication and reactivation. FASEB Journal, 2019, 33, 8280-8293.	0.5	17
27	Molecular motor protein KIF5C mediates structural plasticity and long-term memory by constraining local translation. Cell Reports, 2021, 36, 109369.	6.4	15
28	Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV. Colloids and Surfaces B: Biointerfaces, 2020, 194, 111174.	5.0	14
29	The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency. Journal of Virology, 2021, 95, .	3.4	10
30	Next-Generation Human Cerebral Organoids as Powerful Tools To Advance NeuroHIV Research. MBio, 2021, 12, e0068021.	4.1	10
31	Modeling HIV-1 Latency Using Primary CD4 ⁺ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	9
32	Cellâ€Permeable Peptides Containing Cycloalanine Residues. Angewandte Chemie, 2016, 128, 12827-12832.	2.0	8
33	Cure and Long-Term Remission Strategies. Methods in Molecular Biology, 2022, 2407, 391-428.	0.9	5
34	Somatic Cell Genetic Analyses to Identify HIV-1 Host Restriction Factors. Methods in Molecular Biology, 2009, 485, 235-255.	0.9	4
35	Analysis of RNA Processing Reactions Using Cell Free Systems: 3' End Cleavage of Pre-mRNA Substrates in vitro . Journal of Visualized Experiments, 2014, , .	0.3	1
36	Optimizing In Vitro Pre-mRNA 3′ Cleavage Efficiency: Reconstitution from Anion-Exchange Separated HeLa Cleavage Factors and from Adherent HeLa Cell Nuclear Extract. Methods in Molecular Biology, 2017, 1507, 179-198.	0.9	0